Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.

[1]  A. Yıldırım,et al.  Impact of delay in cystoscopic surveillance on recurrence and progression rates in patients with non‐muscle‐invasive bladder cancer during the COVID‐19 pandemic , 2021, International journal of clinical practice.

[2]  W. Horninger,et al.  The “COVID-19 Pandemic Gap” and Its Influence on Oncologic Outcomes of Bladder Cancer , 2021, Cancers.

[3]  Mike W. Thompson,et al.  Use of Telehealth by Surgical Specialties During the COVID-19 Pandemic. , 2021, JAMA surgery.

[4]  P. Dasgupta,et al.  Urinary biomarkers to mitigate diagnostic delay in bladder cancer during the COVID-19 era , 2020, Nature Reviews Urology.

[5]  B. Jacobs,et al.  Referral pattern for urologic malignancies before and during the COVID-19 pandemic , 2020, Urologic Oncology: Seminars and Original Investigations.

[6]  C. Ellimoottil,et al.  Video Visits as a Substitute for Urological Clinic Visits , 2020, Urology.

[7]  V. Ficarra,et al.  Telehealth in Urology: A Systematic Review of the Literature. How Much Can Telemedicine Be Useful During and After the COVID-19 Pandemic? , 2020, European Urology.

[8]  M. Staehler,et al.  Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver? , 2020, European Urology Focus.

[9]  C. Sundaram,et al.  Delaying Cancer Cases in Urology during COVID-19: Review of the Literature. , 2020, The Journal of urology.

[10]  D. Margel,et al.  Changes in Urology After the First Wave of the COVID-19 Pandemic , 2020, European Urology Focus.

[11]  I. Tsaur,et al.  Telemedicine Online Visits in Urology During the COVID-19 Pandemic—Potential, Risk Factors, and Patients’ Perspective , 2020, European Urology.

[12]  S. Porten,et al.  An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer , 2020, BMC urology.

[13]  L. Kiemeney,et al.  The global burden of urinary bladder cancer: an update , 2019, World Journal of Urology.

[14]  Y. Lotan,et al.  Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. , 2019, European urology.

[15]  F. Ameye,et al.  Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles , 2019, International journal of molecular sciences.

[16]  M. Babjuk,et al.  An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer , 2018, World Journal of Urology.

[17]  P. O'sullivan,et al.  Clinical Utility of Cxbladder Monitor for Patients with a History of Urothelial Carcinoma: A Physician–Patient Real-World Clinical Data Analysis , 2018, Oncology and Therapy.

[18]  Y. Lotan,et al.  Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. , 2017, Urologic oncology.

[19]  Y. Lotan,et al.  Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study , 2017, The Journal of urology.

[20]  J. Seigne,et al.  THE BURDEN OF CYSTOSCOPIC BLADDER CANCER SURVEILLANCE – ANXIETY, DISCOMFORT, AND PATIENT PREFERENCES FOR DECISION MAKING: PD06‐06 , 2017, Urology.

[21]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[22]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[23]  Tuan Dinh,et al.  The Health Economics of Bladder Cancer: An Updated Review of the Published Literature , 2014, PharmacoEconomics.

[24]  Karim Chamie,et al.  Recurrence of high‐risk bladder cancer: A population‐based analysis , 2013, Cancer.

[25]  T. Skolarus,et al.  Disparities in bladder cancer. , 2012, Urologic oncology.

[26]  O. Sansom,et al.  Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis , 2011, Cell Death and Disease.

[27]  G. Mowatt,et al.  Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. , 2010, Health technology assessment.

[28]  E. Steyerberg,et al.  Non‐muscle‐invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost‐effective alternative? , 2009, BJU international.

[29]  D. Schilling,et al.  Economic aspects of bladder cancer: what are the benefits and costs? , 2009, World Journal of Urology.

[30]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[31]  C. Roehrborn,et al.  Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. , 2003, Urology.